Results 121 to 130 of about 23,315 (198)

Is there still room for pioglitazone in contemporary type 2 diabetes management? [PDF]

Cardiovasc Diabetol
Caruso I.
europepmc   +1 more source

GC-MS metabolomic profiling and PPARγ-targeted <i>in silico</i> approaches for identifying a potential anti-diabetic compound from traditional rice varieties. [PDF]

Front Nutr
Nallusamy S, Vanitha K, Riswana Begam M, Sathyamoorthy NK, Geetha P, Parveen S, Akhansha J, Senbagavalli G, Kokilavani S.   +8 more
europepmc   +1 more source

Modulatory effects of Pioglitazone on the CAF-driven malignant phenotype in cervical cancer: an in vitro bidirectional study. [PDF]

Discov Oncol
Díaz-Palomera CD, González-Lucano LR, García-Bernal JR, de Arellano-Sánchez JAR, Villegas-Pineda JC, Villegas-Pacheco R, Jave-Suárez LF, Pereira-Suárez AL.   +7 more
europepmc   +1 more source

Correction to "Pioglitazone Effect on Glioma Stem Cell Lines: Really a Promising Drug Therapy for Glioblastoma?" [PDF]

PPAR Res
europepmc   +1 more source

Pioglitazone Attenuates Sepsis-Associated Acute Kidney Injury by Modulating TLR-4/NF-κB Signaling and Improving Survival and Renal Function. [PDF]

J Clin Med
Hacım NA, Akbaş A, Akbaş B, Ercan G, Serdaroglu A, Aygun H, Erbas O.   +6 more
europepmc   +1 more source

Effects of Zaozhu Yinchen Decoction on a Rat Model of Nonalcoholic Steatohepatitis via Regulation of Myeloid-Derived Suppressor Cells. [PDF]

Hepat Med
Zhang W, Wang Y, Liu Y, Zheng X, Wang T, Kwan X, Liu R, Liu Q, Zhuang H, Liang H, Chen S.   +10 more
europepmc   +1 more source

PPAR-γ agonist Inactivate Cellular Senescence by Inhibiting SIRT1 Signaling to Confer Increased Sensitivity to Olaparib in Ovarian Cancer Cells. [PDF]

Saudi J Med Med Sci
Wang Z, Miao W, Gao J, Zhang X.
europepmc   +1 more source

Modifying muscle metabolic dysregulation in inclusion body myositis with pioglitazone: a single-arm trial. [PDF]

Nat Commun
Adler BL, Bene MR, Zhang C, Say C, Khare P, Mecoli C, Tiniakou E, Paik JJ, Chung T, Darrah E, Lloyd T, Pagkatipunan R, McGowan M, Mears A, Vernon HJ, Christopher-Stine L, Le A, Albayda J.   +17 more
europepmc   +1 more source

Residual bile flow shapes PPARγ-mediated antifibrotic responses in experimental segmental cholestasis. [PDF]

Sci Rep
Gonçalves JO, Mafra CAM, Castro I, Cogliati B, Bando SY, Teodoro WR, Serafini S, Ferreira LF, Moreira-Filho CA, Tannuri U, Tannuri ACA.   +10 more
europepmc   +1 more source

Clinical efficacy of PPAR agonists in the treatment of nonalcoholic fatty liver disease. [PDF]

Front Pharmacol
Li X, Zhang J, Wei B, Tong H.
europepmc   +1 more source